Propylthiouracil Pill
PreclinicalSmall molecule
Propylthiouracil Pill is one of 11 small molecule programs targeting Thyroiditis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Thyroiditis
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Glucophage
Boehringer IngelheimPhase 2
Thyroxine
WWashington University School of Medicine
Phase 2
Plaquenil
Alnylam PharmaceuticalsPreclinical
Treatment as Usual
AAB Biotics, SA
Preclinical
Selenium
SSWOG Cancer Research Network
Preclinical
Potassium Iodide
DDawnrays Pharmaceutical (Holdings) Limited
Preclinical
Methimazole Pill
FFirst Affiliated Hospital of Harbin Medical University
Preclinical
Propylthiouracil Pill
FFirst Affiliated Hospital of Harbin Medical University
Preclinical
L-Selenomethionine
SSWOG Cancer Research Network
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Propylthiouracil Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details